4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)

R. Sullivan, I.A. Olusegun, B.O. Anderson, R. Audisio, P. Autier, A. Aggarwal, C. Balch, M. Brennan, A. Dare, A. D’Cruz, A. Eggermont, K. Fleming, L. Hagander, C.A. Herrera, A.M. Ilbawi, J.F. Ji, T.P. Kingham, J. Liberman, A.J.M. Leather, J.G. Meara, S.S. Murthy, S. Omar, G.P. Parham, C.S. Pramesh, R. Riviello, D. Rodin, L. Santini, S.V. Shrikhande, M. Shrime, R. Thomas, A.T. Tsunoda, D. Watters, S. Wang, Y.L. Wu, F. Van de Velde, U. Veronesi, M. Zeiton, A. Purushotham. Institute of Cancer Policy, Kings Health Partners Comprehensive Cancer Centre, and King’s Centre for Global Health; Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, Nigeria; University of Washington School of Medicine in Seattle, and Fred Hutchinson Cancer Research Center, USA; British Association of Surgical Oncology and European Society for Surgical Oncology, u0026 University of Liverpool, UK; 5 International Prevention Research Institute, Lyon, France; 6 Institute of Cancer Policy, King’s College London u0026 Guy’s u0026 St Thomas NHS Foundation Trust u0026 London School Hygiene and Tropical Medicine, UK; Johns Hopkins Institute for Clinical and Translational Research, John Hopkins, USA; Memorial Sloan Kettering Comprehensive Cancer Centre, USA; Centre for Global Health Research, St Michael’s Hospital u0026 Department of Surgery, University of Toronto; Tata Memorial Hospital, Head u0026 Neck Surgery, India; Gustave Roussy Cancer Institute, and University Paris Sud, France; Green Templeton College, University of Oxford, Oxford University Hospitals NHS Trust, UK; University Cheikh Anta DIOP and Grand Yoff General Hospital, Dakar, Senegal; Paediatric Surgery and Global Paediatrics, Department of Clinical Sciences Lund, Lund University; Cabinet of the Minister, Ministry of Health, Chile u0026 Department of Public Health; MD Anderson Comprehensive Cancer Centre, USA and Union for International Cancer Control (UICC); Peking University Cancer Hospital u0026 Institute, Beijing, China and Chinese Anti-Cancer Association (CACA); Memorial Sloan Kettering Cancer Center, USA; McCabe Centre for Law and Cancer, Melbourne, Australia; King’s Centre for Global Health, King’s Health Partners and King’s College London, London, UK; Program in Global Surgery and Social Change, Harvard Medical School, USA; Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard School of Public Health; National Cancer Institute, Cairo University, Cairo, Egypt; Department of Obstetrics and Gynecology, Lineberger Comprehensive Cancer Center, University of North Carolina; Department of Surgical Oncology, Tata Memorial Centre, Mumbai India; Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard School of Public Health; Department of Radiation Oncology, University of Toronto, Canada; INCA, Brasil; Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Harvard Interfaculty Initiative in Health Policy u0026 Clinical Instructor, Harvard Medical School, USA; Department of Health, State of Victoria Chief Advisor, Australia; Gyne-Oncology Department, Barretos Cancer Hospital, Barretos, Brazil; Royal Australasian College of Surgeons, and Deakin University and Barwon Health, Geelong, Victoria; Peking University People’s Hospital, Chinese College of Surgeons, China; Guangdong General Hospital u0026 Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Chinese Society of Clinical Oncology; Endocrine u0026 Gastrointestinal Surgery, Leiden University Medical Centre, Netherlands; European Institute of Oncology, Milan; Sadeq Institute, Libya and Trauma u0026 Orthopaedic Rotation, North-West Deanery, UK; Kings Health Partners Integrated Cancer Centre, King’s College London and Guy’s u0026 St Thomas NHS Foundation Trust, London, UK